Literature DB >> 33180939

Prognostic threshold for circulating tumour cells in patients with pancreatic and midgut neuroendocrine tumours.

Dalvinder Mandair1,2, Mohid S Khan1,2,3, Andre Lopes4, Luke Furtado O'Mahony5, Leah Ensell2, Helen Lowe2, John A Hartley2, Christos Toumpanakis1, Martyn Caplin1, Tim Meyer2,6.   

Abstract

BACKGROUND: Circulating tumour cells (CTCs) are detectable in patients with NET and are accurate prognostic markers although the optimum threshold has not been defined.
OBJECTIVE: To define optimal prognostic CTC threshold in pancreatic and midgut NET. PATIENTS AND METHODS: CellSearch was used to enumerate CTCs in 199 patients with metastatic pancreatic (PanNET) (90) or midgut NET (109). Patients were followed for progression free survival (PFS) and overall survival (OS) for a minimum of 3 years or until death.
RESULTS: AUROC for progression at 12 months in PanNET and midgut NET identified the optimal CTC threshold as ≥1 and ≥2 respectively. In multivariate logistic regression analysis, these thresholds were predictive for 12 month progression with OR of 6.69 (p< 0.01) for PanNET and 5.88 (p<0.003) for midgut. The same thresholds were found to be optimal for predicting death at 36 months with an OR of 2.87 (p< 0.03) and 5.09 (p<0.005) for PanNET and midgut NET respectively. In multivariate Cox hazard regression analysis for PFS in PanNET, ≥ 1 CTC had HR 2.6 (p <0.01) whilst ≥ 2 CTCs had HR 2.25 (p < 0.01) in midgut NET. In multivariate analysis OS in PanNET, ≥ 1 CTC had HR 3.16 (p < 0.01) and in midgut NET, ≥ 2 CTCs had HR of 1.73 (p < 0.06).
CONCLUSIONS: The optimal CTC threshold to predict PFS and OS in metastatic PanNET and midgut NET is 1 and 2, respectively. These thresholds can be used to stratify patients in clinical practice and clinical trials.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Circulating tumour cells; Midgut NET; PanNET; neuroendocrine tumour

Year:  2020        PMID: 33180939     DOI: 10.1210/clinem/dgaa822

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  3 in total

1.  Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours.

Authors:  Tim Meyer; Martyn Caplin; Mohid S Khan; Christos Toumpanakis; Shishir Shetty; John K Ramage; Aude Houchard; Kate Higgs; Tahir Shah
Journal:  J Neuroendocrinol       Date:  2022-02-07       Impact factor: 3.870

2.  Circulating Tumor Cell Detection in Lung Cancer Animal Model.

Authors:  Yooyoung Chong; Yong Chae Jung; Euidoo Hwang; Hyun Jin Cho; Min-Woong Kang; Myung Hoon Na
Journal:  J Chest Surg       Date:  2021-12-05

3.  Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms.

Authors:  Alexa Childs; Christopher D Steele; Clare Vesely; Francesca M Rizzo; Leah Ensell; Helen Lowe; Pawan Dhami; Heli Vaikkinen; Tu Vinh Luong; Lucia Conde; Javier Herrero; Martyn Caplin; Christos Toumpanakis; Christina Thirlwell; John A Hartley; Nischalan Pillay; Tim Meyer
Journal:  Endocr Relat Cancer       Date:  2021-08-11       Impact factor: 5.678

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.